4.7 Article

Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats

Journal

BRITISH JOURNAL OF PHARMACOLOGY
Volume 160, Issue 4, Pages 860-877

Publisher

WILEY
DOI: 10.1111/j.1476-5381.2010.00660.x

Keywords

MDMA; caffeine; d-amphetamine; hyperthermia; dopamine; 5-HT serotonin; rat

Funding

  1. Health Research Board of Ireland
  2. NIDA (USA)

Ask authors/readers for more resources

Background and purpose: Caffeine exacerbates the hyperthermia associated with an acute exposure to 3,4 methylenedioxymethamphetamine (MDMA, 'Ecstasy') in rats. The present study investigated the mechanisms mediating this interaction. Experimental approach: Adult male Sprague-Dawley rats were treated with caffeine (10 mg center dot kg-1; i.p.) and MDMA (15 mg center dot kg-1; i.p.) alone and in combination. Core body temperatures were monitored before and after drug administration. Key results: Central catecholamine depletion blocked MDMA-induced hyperthermia and its exacerbation by caffeine. Caffeine provoked a hyperthermic response when the catecholamine releaser d-amphetamine (1 mg center dot kg-1) was combined with the 5-HT releaser d-fenfluramine (5 mg center dot kg-1) or the non-selective dopamine receptor agonist apomorphine (1 mg center dot kg-1) was combined with the 5-HT2 receptor agonist DOI (2 mg center dot kg-1) but not following either agents alone. Pretreatment with the dopamine D-1 receptor antagonist Schering (SCH) 23390 (1 mg center dot kg-1), the 5-HT2 receptor antagonist ketanserin (5 mg center dot kg-1) or alpha(1)-adreno- receptor antagonist prazosin (0.2 mg center dot kg-1) blocked MDMA-induced hyperthermia and its exacerbation by caffeine. Co-administration of a combination of MDMA with the PDE-4 inhibitor rolipram (0.025 mg center dot kg-1) and the adenosine A(1/2) receptor antagonist 9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-C]quinazolin-5-amine 15943 (10 mg center dot kg-1) or the A(2A) receptor antagonist SCH 58261 (2 mg center dot kg-1) but not the A(1) receptor antagonist DPCPX (10 mg center dot kg-1) exacerbated MDMA-induced hyperthermia. Conclusions and implications: A mechanism comprising 5-HT and catecholamines is proposed to mediate MDMA-induced hyperthermia. A combination of adenosine A(2A) receptor antagonism and PDE inhibition can account for the exacerbation of MDMA-induced hyperthermia by caffeine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Clenbuterol activates the central IL-1 system via the β2-adrenoceptor without provoking inflammatory response related behaviours in rats

Karen M. Ryan, Eadaoin W. Griffin, Katie J. Ryan, Riffat Tanveer, Natacha Vanattou-Saifoudine, Eoin N. McNamee, Emer Fallon, Sheena Heffernan, Andrew Harkin, Thomas J. Connor

BRAIN BEHAVIOR AND IMMUNITY (2016)

Article Biochemistry & Molecular Biology

Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder

Kelly Doolin, Chloe Farrell, Leonardo Tozzi, Andrew Harkin, Thomas Frodl, Veronica O'Keane

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Article Psychiatry

DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to early life emotional abuse

Chloe Farrell, Kelly Doolin, Niamh O'Leary, Chaitra Jairaj, Darren Roddy, Leonardo Tozzi, Derek Morris, Andrew Harkin, Thomas Frodl, Zsofia Nemoda, Moshe Szyf, Linda Booij, Veronica O'Keane

PSYCHIATRY RESEARCH (2018)

Editorial Material Immunology

Ketamine and depression: A special kase for kynurenic acid?

Andrew Harkin, Declan M. McLoughlin

BRAIN BEHAVIOR AND IMMUNITY (2019)

Article Neurosciences

L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats

Eoin O'Neill, Rosa Chiara Goisis, Ruth Haverty, Andrew Harkin

JOURNAL OF NEUROSCIENCE RESEARCH (2019)

Article Behavioral Sciences

L-alpha-amino adipic acid provokes depression-like behaviour and a stress related increase in dendritic spine density in the pre-limbic cortex and hippocampus in rodents

J. David, S. Gormley, A. L. McIntosh, V. Kebede, G. Thuery, A. Varidaki, E. T. Coffey, A. Harkin

BEHAVIOURAL BRAIN RESEARCH (2019)

Article Pharmacology & Pharmacy

Pharmacological targeting of β2-adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease

Eoin O'Neill, Justin D. Yssel, Caoimhe McNamara, Andrew Harkin

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Article Neurosciences

Kynurenic Acid Protects Against Reactive Glial-associated Reductions in the Complexity of Primary Cortical Neurons

Kate O'Reilly, Katherine O'Farrell, Oivind Midttun, Yuliia Rakovets, Jennifer David -Bercholz, Andrew Harkin

Summary: This study demonstrates that brain glia produce neuroactive metabolites via tryptophan-kynurenine catabolism and play a role in reactive glial associated neurodegeneration. Results suggest that inhibiting the kynurenine pathway (KP) metabolites can protect against neuronal atrophy associated with reactive glia.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2021)

Article Clinical Neurology

PBMC telomerase activity in depression and the response to electroconvulsive therapy

Karen M. Ryan, Martha Finnegan, Andrew Harkin, Declan M. McLoughlin

Summary: The study found no significant association between telomerase activity and depression, the therapeutic response to ECT, or exposure to adversity.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)

Review Pharmacology & Pharmacy

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Rebecca Maher, Almudena Moreno-Borrallo, Dhruvi Jindal, Binh T. Mai, Eduardo Ruiz-Hernandez, Andrew Harkin

Summary: Nanomedicine focuses on developing nanocarriers to improve drug delivery to the brain for the treatment of neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers have advantages in delivering drugs to the central nervous system (CNS) due to their safety, drug loading capacity, and controlled release properties. These carriers have shown potential in penetrating the blood-brain barrier (BBB) and have been extensively studied in glioblastoma, epilepsy, and neurodegenerative disease models. Intranasal administration has emerged as an attractive route to bypass the BBB using tailored nanocarriers. This review explores the characteristics of polymeric and lipid-based nanocarriers and their potential for CNS drug repurposing, as well as the progress in intranasal drug delivery for neurological diseases.

PHARMACEUTICS (2023)

Article Behavioral Sciences

Regional specific modulation of neuronal activation associated with nitric oxide synthase inhibitors in an animal model of antidepressant activity

Eoin Sherwin, Valentina Gigliucci, Andrew Harkin

BEHAVIOURAL BRAIN RESEARCH (2017)

Article Pharmacology & Pharmacy

Amitriptyline protects against TNF-α-induced atrophy and reduction in synaptic markers via a Trk-dependent mechanism

Eimear O'Neill, Billy Kwok, Jennifer S. Day, Thomas J. Connor, Andrew Harkin

PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)

No Data Available